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Abstract
Congenital long QT syndrome (LQTS) is a genetic disease that predisposes affected individuals to arrhythmias, syncope, and sudden death.
Mutations in several ion channel genes have been discovered in different families with LQTS: KCNQ1 (KVLQT1, LQT1), KCNH2 (HERG,
LQT2), SCN5A (LQT3), KCNE1 (minK, LQT5), and KCNE2 (MiRP1, LQT6). Previously, the P448R-KVLQT1 missense mutation has been
reported as an LQT1-causing mutation. In this report, we demonstrate the presence of the P448R polymorphism in two, unrelated Chinese
LQTS families. Although absent from 500 reference alleles derived from 150 white and 100 African-American subjects, P448R was present
in 14% of healthy Chinese volunteers. Given the inconsistencies between the genotype (LQT1) and clinical phenotype (LQT2) in our two
LQTS families, together with the finding that the P448R appears to be a common, ethnic-specific polymorphism, mutational analysis was
extended to the other LQTS-causing genes resulting in the identification of distinct HERG missense mutations in each of these two families.
Heterologous expression of P448R-KVLQT1 yielded normal, wild-type (WT) currents. In contrast, the two unique HERG mutations resulted
in dominant-negative suppression of the WT HERG channel. Our study has profound implications for those engaged in genetic research.
Importantly, one child of the original proband was initially diagnosed with LQT1 based upon the presence of P448R-KVLQT1 and was treated
with beta-blockers. However, he did not possess the subsequently determined LQT2-causing mutation. On the other hand, his untreated
P448R-negative brother harbored the true, disease-causing HERG mutation. These findings underscore the importance of distinguishing
channel polymorphisms from mutations pathogenic for LQTS and emphasize the importance of using appropriate ethnically matched controls
in the genotypic analysis of LQTS.
© 2004 Elsevier Ltd. All rights reserved.
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1. Introduction
Congenital long QT syndrome (LQTS) is a heritable dis-
order associated with delayed cardiac repolarization, pro-
longed electrocardiographic QT intervals, development of
ventricular arrhythmias, and sudden death. Mutations in at
least six cardiac ion channel genes have been discovered in
different families with LQTS: KCNQ1 (KVLQT1, LQT1),
KCNH2 (HERG, LQT2), SCN5A (LQT3), KCNE1 (minK,
LQT5), KCNE2 (MiRP1, LQT6) and KCNE2 (Kir 2.1,
LQT7)[1–10] (for review see Ref. [11]). More recently, a
mutation in ANKB encoding ankyrin-B (also known as
ankyrin-2), a member of a family of membrane adapters, has
been shown to underlie LQT4 [12].
KVLQT1 is located on chromosome 11p5.5. The gene
encodes a voltage-gated K+ channel a subunit. Mutations of
KVLQT1 cause LQTS type 1 (LQT1), the most common
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form of LQTS. KCNE1, located on chromosome 21, encodes
a 129-amino acid protein, which co-assembles with KVLQT1
to form a slowly activating delayed-rectifier K+ channel (IKs)
[13]. Mutations in HERG, located on chromosome 7q35–
q36, cause LQTS type 2 (LQT2) and represent 45% of the
known LQTS defects. This gene encodes an a subunit that
forms cardiac IKr, a rapidly activating delayed-rectifier K
+
channel [10]. KCNE2 is located on chromosome 21 and
co-assembles with HERG a subunits to form cardiac IKr
channels [6]. Both IKr and IKs are responsible for termination
of the plateau phase of the action potential (AP).
Mutations in SCN5A associated with LQTS destabilize
the channel inactivation gate, leading to a resultant AP pro-
longation, i.e. gain-of-function mutations. K+ channels, on
the other hand, consist of four identical pore-forming sub-
units (a subunits) that co-assemble to form a functional
channel together with smaller b subunits; this is in contrast to
the Na+ and Ca2+ channels, which are composed of one
pore-forming subunit (a subunit) that has a tetrameric-repeat
structure associated with smaller b subunits [14]. At least two
molecular mechanisms account for reduced KVLQT1,
HERG, KCNE1, and KCNE2 function in LQTS [11]. In the
first, abnormal subunits are formed that do not assemble with
normal subunits. These loss-of-function mutations result in a
~50% reduction in the number of functional channels. In the
second mechanism, abnormal subunits can assemble with
normal subunits, forming heterotetramers with varying sto-
ichiometry. However, channels formed from normal and mu-
tant subunits have reduced or no function. The net effect is a
greater than 50% reduction in channel function, or a
dominant-negative effect on the wild-type (WT) subunits.
Previously, the P448R-KVLQT1 missense mutation has
been reported as an LQT1-causing mutation [15]. In our
current study, we demonstrated the presence of P448R in two
Chinese LQTS families as well as in 14% of normal healthy
volunteers of Chinese descent without clinical evidence or
family history of LQTS. These findings suggest that P448R-
KVLQT1 represents an ethnic-specific, common polymor-
phism rather than an LQT1-causing mutation. Consequently,
mutational analysis was extended to additional LQTS-
causing genes resulting in the identification of distinct HERG
missense mutations in each of the two patients. To directly
document the significance of the two newly identified HERG
variants as the LQT2 disease-causing mutations, we per-
formed functional analysis of the two novel HERG mutations
identified in the two patients as well as the previously de-
scribed KVLQT1 mutation, P448R.
2. Materials and methods
2.1. LQTS subjects
The proband from Family #1 was diagnosed with LQTS in
1985 after several syncopal events while crossing the street
or when sitting. Twelve-lead EKG showed a prolonged QT
interval (QTC = 500 ms). There was no family history of
sudden death. She was treated with a dual-chamber pace-
maker and beta-blocker therapy. She was found to have a
KVLQT mutation [15], although her QT interval shortened
with exercise and her 12-lead EKG showed low-amplitude,
notched T waves more consistent of the LQT2 (HERG)
subtype [16]. Her asymptomatic children were genotyped,
and the 7-year-old son was found to carry the same LQT1
mutation. He was treated with beta-blocker medications and
was offered a defibrillator implant. The family was of Chi-
nese descent.
The proband from Family #2 was diagnosed with LQTS in
2000 after syncopal events at age 27 and 33 while sitting. Her
12-lead EKG (QTC = 520 ms; Fig. 1) also demonstrated the
same low-amplitude, notched T waves as Patient #1, and her
QT interval also shortened with exercise. Her DNA was
screened for LQTS mutations, and she was found to share the
exact same base pair mutation in the KVLQT gene as Patient
#1, although the two women were unrelated. She was also of
Chinese descent.
2.2. Control subjects
Genomic DNA from 300 unrelated, healthy control sub-
jects (100 African-American, 150 Caucasians/whites of Eu-
ropean ancestry, and 50 Chinese) was obtained from volun-
teers without a personal or family history of LQTS or
syncope. Ethnic background was by self-report that all four
grandparents belonged to that ethnic group. Chinese volun-
teers also underwent 12-lead EKG recordings. The human
study protocol was approved by the University of California,
Davis Institutional Review Board. All patients gave informed
consent for the study.
2.3. Mutational analyses
Mutation analyses were performed as previously de-
scribed [17]. Protein-encoding exons of KVLQT1 and HERG
were amplified from genomic DNA by polymerase chain
reaction using the full-length genomic sequence and previ-
ously published intron- and exon-based primers [18]. The
mutations were detected by denaturing high performance
liquid chromatography using a Transgenomic WAVE
(Omaha, Nebraska, NE) system, as previously described
[17,19]. The precise sequences of the mutations were deter-
mined by sequence analysis.
2.4. Mutation nomenclature
All mutations were denoted using known and accepted
nomenclature [20]. The single-letter amino acid code was
used to designate missense mutations using the A422T for-
mat, i.e. at amino acid 422, the WT amino acid, alanine (A),
is replaced by a threonine (T) on one of the alleles.
2.5. Site-directed mutagenesis
Point mutations were introduced into HERG (H562P and
A422T) and KVLQT1 (P448R) K+ channels in the plasmid
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Fig. 1. (A) Twelve-lead EKG obtained from Patient #2 showing evidence of QT prolongation (QTc = 520 ms) as well as low-amplitude, notched T waves. (B)
DNA sequence analysis of amplified exon 10 of KVLQT1 of one of the probands compared to one of the seven of the 50 normal controls (14%) which reveals
a C-to-G substitution at position 1343 and causes the P448R substitution (the purported LQT1 mutation). Both Patients #1 and #2 were further screened for
possible mutations in HERG gene and were found to have unique, LQT2 mutations. (C,D) DNA sequence analysis of amplified exons 7 and 6 of HERG of the
two probands compared to the reference alleles, which reveal an A-to-C substitution at position 1685 and causes the H562P substitution (in Patient #1) and a
G-to-A substitution at position 1264 and causes the A422T substitution (in Patient #2), respectively. The two HERG missense mutations (A422T and H562P)
are localized to S1 and S5 transmembrane segments of the HERG channel, respectively. (E) Pedigree of family of Patient #1. Squares indicate males and circles,
females. Affected individuals are represented by solid symbols while unaffected individuals are empty symbols.+ve and –ve represent positive and negative,
respectively.
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vector using QuickChange™ Site-Directed Mutagenesis kit
(Stratagene, La Jolla, CA). Constructs were confirmed with
restriction mapping and DNA sequencing.
2.6. Transient transfection of HERG and KVLQT1 K+
channels
HEK 293 cells were maintained in Dulbecco’s modified
Eagle’s medium containing 10% fetal bovine serum, 2 mM
L-glutamine, and 1% penicillin and streptomycin. Cell cul-
tures were kept at 37 °C in a 5% CO2 incubator. Cells were
transiently transfected with HERG cDNA, green fluorescent
protein (GFP), and hMiRP1 cDNA (hKCNE2) (kindly pro-
vided by Dr. Tomaselli, Johns Hopkins University, Balti-
more, MD) using the calcium phosphate precipitation
method (Invitrogen, Carlsbad, CA). GFP-positive cells were
identified using the epifluorescence system and studied
within 24–48 h of transfection.
Chinese Hamster ovarian (CHO) cells were maintained at
37 °C in HAM’s F-12 medium containing 10% fetal bovine
serum supplemented with 1% penicillin, streptomycin, and
amphotericin. Cells were transiently transfected with KV-
LQT1, KCNE1, (kindly provided by Pr. H. Bradley Nuss,
University of Maryland, Baltimore, MD), and GFP cDNA
using the lipofectamine method (Invitrogen). Electrophysi-
ologic recordings were performed 24–48 h after transfection.
CHO cells were used for KVLQT1 channel expression be-
cause these cells tend to express higher KVLQT1 current
density. No direct comparison was made for current ex-
pressed in the two different cell types.
Mutant and the corresponding WT channels cDNA were
transfected in parallel experiments using the same sets of
cells. The amount of cDNA used for mutant and WT chan-
nels was kept constant throughout all experiments. Current
recordings were then performed at the same time point in
culture.
2.7. Electrophysiologic recordings
Membrane currents were measured using whole-cell
patch-clamp techniques [21]. Cells were bathed in solution
containing (in mmol/l) NaCl 140, KCl 5.4, MgCl2 1, N-2-
hydroxyethylpiperazine-N-2-ethanesulphonic acid (HEPES)
10, glucose 10, and CaCl2 2, pH 7.4 (adjusted with NaOH).
Fig. 1. (continued)
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The pipette solution contained (in mmol/l) KCl 140, MgCl2
1, HEPES 10, EGTA 5, and MgATP 4, pH 7.3 (adjusted with
KOH). Uncompensated capacitance currents in response to
small hyperpolarizing voltage steps were recorded for offline
integration as a means of measuring cell capacitance. All
experiments were performed at room temperature (22–
23 °C) using an Axopatch 200A patch-clamp amplifier
(Axon Instruments, Foster City, CA). Voltage commands and
data collection were controlled using custom-written soft-
ware. For whole-cell current recordings, the cell capacitance
and series resistance were compensated. In general, 60–80%
of the series resistance was compensated. Current records
were filtered at 2 kHz and sampled at 10 kHz using a four-
pole Bessel filter.
Voltage protocols used in this study for evaluating HERG
and its mutation are as follows (see also inset in the Figures):
(1) voltage-dependent activation: prepulse for 4 s from –80 to
80 mV in 10 mV steps, test pulse to –50 mV for 6 s. (2)
Activation kinetics: incremental prepulse duration from
0.035 to 0.49 s at 0–60 mV in 20 mV steps, test pulse for 0.2 s
at –120 mV. (3) Steady-state inactivation and recovery from
inactivation: prepulse to –140 from holding potential of
20 mV, depolarization to 50 mV in 10 mV steps for 0.03 s and
a test pulse to 20 mV for 0.17 s. (4) Instantaneous current–
voltage relation and deactivation kinetics: prepulse to
–80 mV from holding potential of 20 mV for 0.03 s, test pulse
to –140, depolarization to 40 mV in 10 mV steps for 1.6 s.
Voltage protocol used for determining KVLQT1 and P448R
mutant channel for voltage-dependent activation: prepulse
for 5 s from –80 to 90 mV in 10 mV steps, test pulse to
–50 mV for 5 s. Pooled data are presented as mean ± SEM.
Statistical comparison was performed using the Student’s
t-test and analysis of variance (where appropriate) with
P < 0.05 considered significant.
3. Results
Patient #1 was diagnosed with LQTS after several synco-
pal events at age 27. She was treated with a dual-chamber
pacemaker and beta-blocking agents. She was genotyped as
LQT1 [11] although her QT interval shortened with exercise
and showed low-amplitude, notched T waves more charac-
teristic of LQT2 [16]. Her 7-year-old son was found to have
the same LQT1 mutation and was started on beta-blocker
therapy and was offered a defibrillator. She was of Chinese
descent.
Patient #2 was diagnosed with LQTS after syncopal
events at age 27 and 33 while sitting; the latter occurred on
beta-blocker therapy. She was found to have the same LQT1
mutation as Patient #1 although they are not related. She also
demonstrated low-amplitude, notched T waves on EKG,
again more typical of LQT2. Patient #2 was also of Chinese
descent. Fig. 1A shows the 12-lead EKG obtained from
Patient #2 showing evidence of QT prolongation.
In view of the discrepancy between the genotypic and
phenotypic data on the two patients as well as the fact that
the two probands were genetically unrelated but were
both of Chinese descent, we questioned whether the pre-
viously found LQT1 mutation in the two patients repre-
sented a polymorphism rather than a disease-causing
mutation. We decided to screen 50 healthy volunteers of
Chinese descent who were not related to either patient
and had no family or personal history suggestive of
LQTS. Seven of the 50 controls (14%) carried the same
purported LQT1 mutation (Fig. 1B) and had an average
QTC interval on EKG of 406 ms. In contrast, none of the
150 Caucasian or 100 African-American controls carried the
identified LQT1 variant.
Both patients were further screened for possible HERG
mutations and were found to have unique HERG variants
(A422T and H562P, Fig. 1C,D). The two HERG variants
were absent in not only the 500 ethnically unmatched refer-
ence alleles but also absent in the 100 alleles derived from
50 ethnically similar Chinese volunteer. The two HERG
variants were localized to the S1 and S5 transmembrane
segments of the HERG channel, respectively. Patient #1’s
7-year-old son (who was being treated for LQTS) does not
carry the newly identified HERG variant but her 5-year-old
son (who was not being treated for LQTS) is positive for the
HERG variant. Fig. 1E shows the pedigree of family of
Patient #1. Affected individuals are represented by solid
symbols while unaffected individuals are represented by
empty symbols. Patient #2’s infant daughter is LQT1 positive
and LQT2 positive and is taking beta-blocker therapy.
To document directly that the previously reported P448R
mutation in KVLQT1 most likely represents a genetic poly-
morphism present in the Chinese population, we performed
functional analysis of the P448R mutant channel using het-
erologous expression system in CHO cells. Fig. 2A shows
the representative IKs comparing WT KVLQT1/KCNE1 and
P448R/KCNE1 from a holding potential of –80 mV. The
summary data for the current density–voltage relations are
shown in Fig. 2B. The voltage dependence of current activa-
tion was determined by fitting the relationship between tail
currents at various test potentials with the Boltzmann func-
tion (Fig. 2C). The activation curve for KVLQT1/KCNE1
current shows a half-activation voltage (V1/2) of
50.14 ± 3.82 mV and a slope factor of 20.84 ± 2.54; n = 10.
The values obtained from P448R/KCNE1 current are similar
(a V1/2 of 53.32 ± 4.52 mV and a slope factor of 21.63 ± 2.79;
n = 12).
To assess further whether the identified HERG mutations
lead to alteration in channel function, we examined the func-
tion of the mutant channels compared to WT HERG channel
in HEK 293 cells. Fig. 3A shows examples of IKr from WT
HERG K+ channel co-expressed with KCNE2 subunit elic-
ited using depolarization steps from a holding potential of
–80 mV. Panels B and C shows currents recorded from the
two identified HERG missense mutations co-expressed with
KCNE2 subunit. Both missense mutations resulted in a sig-
nificant decrease in current density (note the difference in
scale bar from WT current traces in Panel A). To test whether
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these mutations could result in the dominant-negative sup-
pression of the WT IKr current, we co-expressed the mutant
channel together with WT HERG and KCNE2 subunits in the
ratio of 1:1:1. Panels D and E show a significant dominant-
negative suppression on the WT HERG K+ current from
co-expression with either of the missense mutations. Sum-
mary data are shown in Panels F and G illustrating a signifi-
cant decrease in the WT current density at all test potentials
from co-expression with the mutant channels. The WT
HERG K+ current shows a rectification with maximum out-
ward current at a test potential of +10 mV, in contrast, the
rectification was lost with co-expression with the mutant
channels. These findings suggest that the two identified mis-
sense mutations in HERG K+ channel are likely the disease-
causing mutations in the two LQTS families.
Tail current amplitude, normalized to cell capacitance,
was used to construct the activation curves shown in Fig. 4A.
The amplitude of the peak tail current for H562P/
HERG/KCNE2 and A422T/HERG/KCNE2 was significantly
smaller (P < 0.0001) than that of WT HERG/KCNE2. The
threshold activation voltage for WT HERG/KCNE2 current
was close to –50 mV and the current was fully activated at
voltage steps more positive to +10 mV. When fit with Boltz-
mann functions, the half-maximum activation voltage (V1/2)
and slope factor (k) for WT HERG/KCNE2 was
–20.12 ± 0.31 mV and 8.24 ± 0.27, respectively. The values
for A422T/HERG/KCNE2 and H562P/HERG/KCNE2 were
–29.49 ± 1.28 mV (V1/2) and 6.50 ± 1.101 (k) and
–39.77 ± 2.20 mV (V1/2) and 5.04 ± 1.96 (k), respectively
(Fig. 4A).
Fig. 2. Transient expression of the P448R-KVLQT1 mutant channel compared to WT channel in CHO cells. (A) Representative IKs current traces comparing WT
KVLQT1/KCNE1 and P448R/KCNE1 from a holding potential of –80 mV. (B) Summary data showing the current density–voltage relations obtained from
P448R-KVLQT1 compared to WT channels. (C) The voltage dependence of current activation was determined by fitting the relationship between tail currents
at various test potentials with the Boltzmann function. The activation curve for KVLQT1/KCNE1 current shows a half-activation voltage (V1/2) of
50.14 ± 3.82 mV and a slope factor of 20.84 ± 2.54; n = 10. The values obtained from P448R/KCNE1 current are similar (a V1/2 of 53.32 ± 4.52 mV and a slope
factor of 21.63 ± 2.79; n = 12).
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At all test potentials examined (0, 20, 40, and 60 mV), the
activation time constants for H562P or A422T mutant chan-
nels were not significantly different from those of WT chan-
nel (Fig. 4B). The time course for deactivation was examined
by fitting the decay of tail current with the double exponen-
tial function yielding the fast (sfast) and slow (sslow) time
constants (Fig. 4C). There were no significant differences in
the fast or slow deactivation time constants in mutantsA422T
(n = 3) as compared to WT channel (n = 7). However, the
H562P mutant channel showed a significant decrease in slow
deactivation time constants at test potentials of –120 and
–130 mV as compared to WT channel, whereas sfast re-
mained similar. The instantaneous current density and volt-
age (Fig. 4D) showed a significant decrease in the current
amplitude in H562P/HERG/KCNE2 (n = 3) and mutation
A422T/HERG/KCNE2 (n = 3) as compared with WT
Fig. 3. Transient expression ofA422T- and H562P-HERG mutant channel in HEK 293 cells. (A) Representative current traces of IKr from WT HERG K
+ channel
co-expressed with KCNE2 subunit elicited using depolarization steps from a holding potential of –80 mV. (B,C) Representative currents recorded from A422T
and H562P missense mutant channels co-expressed with KCNE2 subunit. Both missense mutations resulted in a significant decrease in current density (note the
difference in scale bar from WT current traces in Panel A). (D,E) Dominant-negative suppression of the WT IKr current when WT HERG channel was
co-expressed with one of the mutant channels and KCNE2 subunit in the ratio of 1:1:1. Summary data are shown in Panels F and G illustrating a significant
decrease in the WT current density at all test potentials from co-expression with the mutant channels.
85D. Sharma et al. / Journal of Molecular and Cellular Cardiology 37 (2004) 79–89
86 D. Sharma et al. / Journal of Molecular and Cellular Cardiology 37 (2004) 79–89
HERG/KCNE2 (n = 8). The estimated reversal potential for
WT HERG/KCNE2 was close to –76 mV, similar to those of
H562P/HERG/KCNE2 and A422T/HERG/KCNE2 (–72 and
–70 mV, respectively). The time constant of recovery from
inactivation was measured as a mono exponential fit to the
rising phase of the tail current. At all test potentials, the
kinetics of recovery from inactivation in H562P (n = 3) and
A422T mutant channels (n = 3) were not significantly differ-
ent from WT channels (n = 6; Fig. 4E). Similarly, there were
no significant differences in the steady-state inactivation be-
tween WT and the two mutant channels (Fig. 4F).
4. Discussion
The KVLQT1 variant C1343G, leading to an amino acid
substitution, P448R in C terminus was previously reported as
an LQT1-causing mutation [15]. In this study, we demon-
strate the presence of P448R in two genetically unrelated
Chinese LQTS families. Although absent among 500 refer-
ence alleles derived from 150 white and 100 African-Ameri-
can subjects, P448R was also present in 14% of normal,
healthy volunteers of Chinese descent, which suggests that
the mutation may represent an ethnic-specific, common
polymorphism rather than an LQT1-causing mutation. To
further ascertain that the P448R-KVLQT1 does indeed repre-
sent a polymorphism, we carried out functional studies using
the heterologous expression system. Expression of P448R-
KVLQT1 yielded normal, WT currents with kinetics that
were indistinguishable from the WT currents. In contrast, the
two unique HERG mutations resulted in significant
dominant-negative suppression of the WT HERG channel
and are most likely the disease-causing mutations in the two
families. Our study underscores the importance of distin-
guishing channel polymorphisms from disease-causing mu-
tations pathogenic for LQTS and emphasizes the importance
of using appropriate ethnically matched controls in the geno-
typic analysis of LQTS. Indeed, one child of the original
proband was initially diagnosed with LQT1 based upon the
presence of the P448R-KVLQT1 variant and was treated with
beta-blockers. However, he did not possess the subsequently
determined LQT2-causing mutation. On the other hand, his
untreated P448R-negative brother harbored the true, disease-
causing HERG mutation and was not being treated for LQTS.
4.1. K+ channel variants
Our data agrees well with previous studies, which sug-
gested that the KVLQT1 variant P448R may represent a
common polymorphism in Asian subjects since the variant
was identified in 22–28% of Japanese subjects [22] and
16.4% of the Asian subjects [19]. However, none of these
prior studies have carried out functional analyses of the
purported channel variants. Importantly, our study using
functional expression further confirms that P448R-KVLQT1
most likely represents a benign polymorphism with no de-
tectable changes in the current kinetics or expression level
compared to the WT channel, and further that the identified
polymorphism was ethnic specific.
Polymorphisms in the human genome are common and
may be implicated in physiological variability or in drug
response in a wide range of diseases [23,24]. Polymorphisms
are well recognized in non-coding regions of DNA where
they may contribute to regulation of gene function. Some
DNA variants have previously been shown to predispose
individuals to the drug-induced, acquired form of LQTS and
have been reported in congenital LQT disease genes
[6,22,25,26]. Indeed, DNA variants in the coding regions of
congenital LQT disease genes have recently been identified
in ~10–15% of affected subjects, predominantly in genes
encoding ancillary subunits [22]. Most of the individuals
with polymorphisms will never have arrhythmias because of
the subtle effect of these polymorphisms upon the channel
function. However, if exposed to additional acquired risk
factors such as medications, hypokalemia, or structural heart
disease, such patients may be at increased risk for arrhyth-
mias or sudden death [25–27]. For ion channel variants, it has
previously been observed that most of the common polymor-
phisms are located in the amino- and carboxy-termini, and
that these regions may be more tolerant of amino acid substi-
tution than other regions of the channel [19]. For the identi-
fied P448R-KVLQT1 variant in our study, there was no his-
tory of drug-induced arrhythmias in any of our healthy
Chinese control subjects. This most likely represents a be-
nign polymorphism as suggested by our heterologous ex-
pression study.
Fig. 4. (A) Voltage dependent of activation was constructed from tail current density. The amplitude of the peak tail current for H562P/HERG/KCNE2 and
A422T/HERG/KCNE2 were significantly smaller (P < 0.0001) than that of WT HERG/KCNE2. Solid lines represent fit to the Boltzmann functions, the
half-maximum activation voltage (V1/2) and slope factor (k) for WT HERG/KCNE2 was –20.12 ± 0.31 mV and 8.24 ± 0.27, respectively. The values for
A422T/HERG/KCNE2 and H562P/HERG/KCNE2 were –29.49 ± 1.28 mV (V1/2) and 6.50 ± 1.101 (k) and –39.77 ± 2.20 mV (V1/2) and 5.04 ± 1.96 (k),
respectively. (B) Activation time constants at test potentials of 0, 20, 40 and 60 mV for H562P or A422T mutant channels were not significantly different from
those of the WT channel. The pulse protocol used is shown in the inset together with representative traces obtained from the WT channel at a test potential of
0 mV. (C) There were no significant differences in the fast or slow deactivation time constants in mutants A422T (n = 3) as compared to the WT channel (n = 7).
However, the H562P mutant channel showed a significant decrease in the slow deactivation time constants at test potentials of –120 and –130 mV as compared
to the WT channel, whereas sfast remained similar. The pulse protocol used is shown in the inset. (D) The instantaneous current density–voltage relations
showing a significant decrease in the current amplitude in H562P/HERG/KCNE2 (n = 3) and mutation A422T/HERG/KCNE2 (n = 3) as compared with WT
HERG/KCNE2 (n = 8). The instantaneous current density–voltage relations were obtained using the same protocol as shown in C. (E) Time constant of recovery
from inactivation was measured as a mono exponential fit to the tail current rising phase. The pulse protocol used is shown in the inset. (F) The steady-state
inactivation obtained using the same protocol as in E from WT and the two mutant channels are shown. Representative traces from the WT channel is shown in
the inset.
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4.2. Specific phenotypes in LQT patients
Specific phenotypes have been associated with the three
main genetic subtypes of LQT1, LQT2, and LQT3 [27,28].
LQT1 appears to be the most adrenaline-sensitive of the
subtypes in that episodes frequently occur during exercise,
swimming, or with strong emotion, and beta-blocker medi-
cations work well at reducing episodes in this subtype [16].
LQT2 is classically associated with auditory stimuli, and
these patients respond variably to beta-blockers [16,29].
LQT3 is relatively rare, representing only 5–10% of all
LQTS patients [11]. Typically they have episodes while
sleeping, and are believed to have the lowest event rate but
highest mortality with events, and may respond well to pace-
maker therapy alone [16,28,30].
The clinical phenotype in our two Chinese probands was
more consistent with the LQT2 subtype including their pre-
sentation, EKG features, and results of exercise testing. In-
deed, the inconsistencies between their published genotype
(LQT1) and their phenotype (LQT2) led us to a renewed
search to uncover their LQT2 mutations.
4.3. Functional analysis
Our results, as well as recent studies suggesting ethnic
differences in cardiac K+ channel variants further under-
scores the fact that extreme caution must be used in assigning
a channel variant the status of a pathogenic channel mutation
causing congenital LQTS. In general, the criteria used in-
clude identification of a non-synonymous variant including
single nucleotide substitutions, deletions and insertions, ab-
sence of that variant in the controls as well as conservation of
that particular amino acid through various species. If a par-
ticular channel variant has been identified in a small number
of affected family members precluding genetic linkage
analysis of multigenerational families, functional analysis
will need to be performed to determine whether the identified
variant results in a functionally abnormal channel.
The “gold standard” of determining which mutations are
benign vs. disease causing is through functional analysis of
the mutations, as we did through patch-clamp analysis. We
demonstrated for the first time in the present study that the
purported P448R polymorphism does not affect the IKs cur-
rent. We have shown that the novel H562P and A4225 muta-
tions in the HERG channel in our probands resulted in
marked reduction of the K+ current, specifically the expected
dominant-negative suppression of the HERG current.
We conclude that the two novel HERG mutations in these
families indeed affect the K+ channel function and are caus-
ative agents for their LQTS. We do not know what, if any,
clinical effects the P448R polymorphism has. It was found in
14% of our healthy Chinese volunteers who had normal EKG
findings and no symptoms suggestive of LQTS.
4.4. Clinical implications
Our study has implications for genetically based research.
In our first LQTS family, the two children of the proband
were given incorrect diagnoses regarding their LQTS status.
One child with the Asian DNA polymorphism was being
treated for a disease he did not have, whereas his affected
brother carried the disease-causing mutation but did not
receive treatment. This study highlights the need to include
members of different ethnic groups as control subjects when
performing genomic DNA studies. Such inclusion should
limit mislabeling ethnically based benign DNA polymor-
phisms as disease-causing mutations.
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